Changeflow GovPing Pharma & Drug Safety Process for Making Aqueous Therapeutic Particle...
Routine Notice Added Final

Process for Making Aqueous Therapeutic Particles with Nanosized Water Clustering

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

USPTO published patent application US20260090957A1 for a process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering between 1-300 nanometers. The invention, assigned to a multi-inventor team, claims improved bioavailability for therapeutic compositions including CBD, PNC-27 peptides, pharmaceuticals, and nutraceuticals through a computer-controlled continuous manufacturing process.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO published patent application US20260090957A1 (filed May 13, 2025, published April 2, 2026) claiming a novel process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering of 1-300 nanometer thickness. The inventors describe an improved computer-controlled, continuous-operation process apparatus that produces AQTP with increased bioavailability compared to conventional drug particles when administered to mammals. The compositions may include cannabinoids (CBD), cell membrane pore-forming peptides (PNC-27), pharmaceuticals, nutraceuticals, proteins, peptides, vitamins, antioxidants, and various other therapeutic or consumer product agents.

Entities in the pharmaceutical manufacturing, drug delivery, and nutraceutical sectors should review the patent claims for freedom-to-operate considerations. The patent covers AQTP compositions and the manufacturing process apparatus for producing nanosized therapeutic particles with claimed bioavailability improvements. The filing represents potential licensing opportunities for drug delivery technologies or competitive intelligence regarding nanoparticle formulation approaches.

What to do next

  1. Review patent claims for freedom-to-operate if manufacturing nanoparticle therapeutic compositions
  2. Evaluate licensing opportunities for AQTP technology if developing related drug delivery systems
  3. Monitor for issued patent and corresponding international filings for global coverage

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness

Application US20260090957A1 Kind: A1 Apr 02, 2026

Inventors

Karl P. Dresdner, Jr., Michael Raymond Cary, Chase Hudson, Nathan A. Beckham

Abstract

The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness between 1 to 300 nanometers wherein the AQTP has increased bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors. The invention provides compositions comprising of AQTP which comprise a substance selected from the group consisting of a cannabinoid such as CBD, a cell membrane pore-forming peptide such as PNC-27, a psychoactive drug, a pharmaceutical, a nutraceutical, a mineral, an anion, a cation, a protein, a peptide, an amino acid, a polymer, a vitamin, an antioxidant, a fertilizer, a chemical, a medical use product, a medical kit use product, a personal consumer use product, a manufacturing use product, an energy use product such as a battery, and any combination thereof.

CPC Classifications

A61J 3/07 A23L 2/52 A61K 9/0095 A61K 9/5115 A61K 9/5192 A61K 31/658 C02F 9/00 A23V 2002/00 C02F 1/001 C02F 1/32 C02F 1/441 C02F 1/4691 C02F 2103/04

Filing Date

2025-05-13

Application No.

19206070

View original document →

Named provisions

Abstract CPC Classifications Inventors Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
May 13th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260090957A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Patients
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 6211 Healthcare Providers
Activity scope
Patent Filing Pharmaceutical Manufacturing Nanoparticle Formulation
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!